As financial pressures and a search for engagement redefine retirement, a new wave of seniors is turning to flexible, low-barrier side gigs. From online tutoring to pet care, these roles leverage lifelong skills without requiring prior formal experience.
The UK pharmaceutical giant AstraZeneca begins trading ordinary shares on the New York Stock Exchange today, a significant upgrade from its previous Nasdaq ADR listing. This move underscores the company's strategic rebalancing towards the United States, its largest market, and raises questions about the long-term relevance of its London listing.
As a Utah murder trial resumes, defense attorneys are pressing to remove the entire county prosecutor's office from the case, arguing the presence of a lead attorney's child at the crime scene creates an untenable conflict. Legal experts weigh the high bar for such motions.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
While trading near 52-week highs can signal strength, it can also precede a correction. We examine three stocks where current valuations may not justify the price tag, urging investors to look beyond the hype.
While robust cash generation signals financial health, it doesn't guarantee stock outperformance. We analyze three cash-rich firms, highlighting one standout and two where strong cash flow masks underlying risks.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
A wave of commercial flight disruptions is pushing a new class of travelers toward private aviation, not for opulence but for reliability. We examine the shifting calculus of air travel and what a seat actually costs.
Amidst recent market volatility driven by regional tensions, a closer look reveals companies with strong fundamentals demonstrating remarkable resilience and growth potential. We examine three such firms that are navigating the uncertainty and positioning themselves for the future.
With a partial government shutdown underway, House Speaker Mike Johnson confronts a dual crisis: securing passage of a federal funding package and mediating an intensifying political battle over the scope and tactics of Immigration and Customs Enforcement operations.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.
Israel is set to partially reopen the Rafah border crossing with Egypt, allowing limited pedestrian movement for Palestinians. The move, a condition of the U.S.-brokered ceasefire, comes amid ongoing tensions and a continued ban on foreign journalists.
Boston Scientific's latest earnings beat and raised guidance, fueled by strong demand for its electrophysiology devices, signal a strategic shift. The company is navigating tariff pressures while expanding margins, with major acquisitions poised to reshape its long-term profile.
Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.
Certified financial planner and popular financial educator Kevin Lum outlines a crucial mindset shift for those nearing or in retirement, urging them to move beyond accumulation and toward purposeful living.
While the FTSE 100 grapples with global headwinds, a segment of smaller UK-listed companies presents distinct opportunities. We examine three firms, each with a market capitalisation over £90 million, that combine financial resilience with specific growth catalysts.
